In conclusion, our results suggest that PKNOX1 has different prognoses in different tumor types, is highly expressed in most tumors and is associated with poor prognosis, and PKNOX1 may serve as a promising prognostic marker in patients with ACC, GBMLGG, KIRP, LGG, LIHC, MESO, SARC, UVM, OV, etc. Here, PKNOX1 is linked to neoplasm.